Is Ozempic maker stock a buy after OpenAI partnership?
The post Is Ozempic maker stock a buy after OpenAI partnership? appeared on BitcoinEthereumNews.com.
Novo Nordisk (NYSE: NVO), the company behind the blockbuster diabetes and weight-loss drug Ozempic, has announced a strategic partnership with OpenAI. The collaboration will integrate advanced artificial intelligence across its operations, from drug discovery and development to manufacturing, supply chains, distribution, and commercial functions, to accelerate the delivery of improved treatments. Pilot programs are already underway in research, manufacturing, and commercial teams, with full global integration targeted by the end of 2026. OpenAI will also support workforce upskilling to enhance AI literacy, positioning Novo Nordisk at the forefront of healthcare AI transformation. The announcement comes amid a challenging NVO stock environment. Shares closed at $37.98 on Monday, up 1.23%, before rising to $38.97 in pre-market trading on April 14, a 2.61% gain as investors reacted to the news. NVO YTD stock price chart. Source: Google Finance Over the past year, the stock has declined 42%, trading well below its 2025 highs within a volatile 52-week range, pressured by competition from Eli Lilly in the GLP-1 market. What’s next for NVO stock price Notably, analyst sentiment, based on eight Wall Street firms tracked by TipRanks, remains cautious, with a consensus ‘Hold’ rating that includes one ‘Buy’ and seven ‘Hold’ recommendations. The average 12-month price target is $43, implying about 13.22% upside from the April 13 close, with estimates ranging from $40 to $47. NVO 12-month stock price chart. Source: TipRanks Fundamentally, Novo Nordisk ended 2025 on a strong note, posting fourth-quarter earnings per share of $1.01, above the $0.90 estimate, and revenue of $12.43 billion, beating forecasts of $11.97 billion. Full-year results also showed solid growth in sales and operating profit at constant exchange rates. However, the 2026 outlook is more subdued, with adjusted sales and operating profit expected to decline between 5% and 13% due to U.S. pricing pressures and…
Filed under: News - @ April 14, 2026 10:34 am